ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1464

Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations

Ganiat Adeogun, Alex Camai, Sarah Green and April Barnado, Vanderbilt University Medical Center, Nashville, TN

Meeting: ACR Convergence 2022

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects females of reproductive age but can affect patients later in life. Late-onset (LO)-SLE is defined as SLE diagnosed at age 50 years or later. Studies characterizing LO-SLE have been conflicting. It is unclear if LO patients have different disease presentations compared to non-late-onset (NLO) patients. Using a de-identified electronic health record (EHR), we assessed demographic, clinical presentation, and SLE autoantibodies in LO vs. NLO-SLE patients.

Methods: We assembled a cohort of SLE patients using a validated and published algorithm that requires ≥ 4 SLE ICD-9 codes and a positive ANA ≥ 1:160. We performed chart review on all SLE patients to ensure diagnosis by a rheumatologist. Age at SLE diagnosis was defined as age at first SLE billing code or age at SLE diagnosis documented in notes, whichever came first. We compared demographics and presence of SLE nephritis, defined by renal pathology or clinical diagnosis by rheumatology or nephrology, in LO-SLE (SLE diagnosis at ≥ 50 years) vs. NLO-SLE (SLE diagnosis < 50 years). We also compared SLE autoantibodies (dsDNA, Smith, RNP, SSA, SSB) in LO vs. NLO patients. Autoantibody status was defined as positive if ever positive.

Results: We identified 123 LO and 402 NLO-SLE patients. Both LO and NLO patients were predominantly female (85% vs. 91%, p = 0.10, Table 1). LO patients were more likely to be White vs. NLO patients (74% vs. 60%, p = 0.005). LO patients were less likely to be of Hispanic ethnicity vs. NLO patients (1% vs. 5%, p = 0.03). Compared to NLO patients, LO patients were less likely to have positive dsDNA (39% vs. 57%, p = 0.001) and RNP (17% vs. 32%, p = 0.02, Table 1). Rates of positive Smith, SSA, and SSB were all similar in LO vs. NLO-SLE patients. When analyzed by decade of age at SLE diagnosis, autoantibody positivity declined with increasing age (Figure 1). LO vs. NLO patients were less likely to develop SLE nephritis (9% vs. 29%, p < 0.001).

Conclusion: LO-SLE patients were less racially and ethnically diverse compared to NLO-SLE patients. LO patients were less likely to have positive SLE autoantibodies and nephritis. With less SLE-specific autoantibodies, LO-SLE patients can pose a diagnostic challenge. Understanding how age impacts SLE disease presentation could help reduce diagnostic delays for SLE patients.

Supporting image 1

Supporting image 2


Disclosures: G. Adeogun, None; A. Camai, None; S. Green, None; A. Barnado, None.

To cite this abstract in AMA style:

Adeogun G, Camai A, Green S, Barnado A. Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/patients-with-late-onset-systemic-lupus-erythematosus-have-different-disease-presentations/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-with-late-onset-systemic-lupus-erythematosus-have-different-disease-presentations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology